A TARGETED ONCOLOGY COMPANY DEVELOPING
BREAKTHROUGH MEDICINES FOR PRECISELY DEFINED PATIENT POPULATIONS

Mirati Therapeutics is transforming the treatment of patients with cancer by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and spread. Our precision oncology strategy seeks to treat the patients most likely to benefit and is driven by 1) drugs that target very specific genetic mutations that cause cancer, and 2) genomic tests that identify patients who carry those driver mutations. The promise of this approach includes better patient outcomes, more efficient cancer treatment and faster drug development.